| Literature DB >> 31752499 |
Sally E Meikle1, Paul Liknaitzky2, Susan L Rossell3, Margaret Ross4, Nigel Strauss5, Neil Thomas2,3, Greg Murray2,3, Martin Williams6, David J Castle7,8.
Abstract
In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use in the clinical environment, including clarification of the profile of people most likely to benefit and those who might experience adverse effects, longer-term outcomes and the role of psychotherapeutic input alongside the drug itself. There are also opportunities to understand better, the neurobiology underpinning its effects.Entities:
Keywords: Psilocybin; depression; psychedelics
Year: 2019 PMID: 31752499 DOI: 10.1177/0004867419888575
Source DB: PubMed Journal: Aust N Z J Psychiatry ISSN: 0004-8674 Impact factor: 5.744